Immunocorrection in treatment and prevention in liver fibrosis and chronic hepatitis С

Abstract

Chronic hepatitis C (HCV) is one of the main problems of modern medicine. Despite the high effectiveness of direct antiviral drugs, disorders associated with liver fibrosis remain even when a stable virological response is achieved.

The aim of the work was to evaluate the results of the use of pharmacopuncture usage with dispersed biomaterial “Alloplant” (DBMA) in the complex treatment of patients with HCV with varying degrees of liver fibrosis.

Material and methods. The results of an open-label, prospective, randomized study of 98 patients with HCV are presented. All patients with HCV were treated with antiviral therapy according to WHO recommendations 2018: a combination of daclatasvir/sofosbuvir for 12 weeks. Patients of the observation group (n=49) – against the background of AVT additionally received DBMA pharmacopuncture to biologically active points according to the method proposed by R.Sh. Mirkhaidarov. The effectiveness of the proposed therapy was evaluated by the dynamics of the immune status, biochemical parameters of liver fibrosis and the results of transient fibroelastography.

Results. A course of antiviral therapy with additional use of DBMA pharmacopuncture for 12 weeks in patients with HCV showed a restoration of T-cell balance and cytokine regulation, a decrease in the concentration of direct and indirect markers of liver fibrosis in blood serum and a decrease in liver fibrosis according to fibroelastography.

Conclusion. The pharmacopuncture of DBMA has an immunocorrective, anti-inflammatory and regenerative effect on hepatocytes and can be recommended as part of the complex therapy of liver fibrosis in HCV patients.

Keywords:chronic viral hepatitis C; dispersed biomaterial “Alloplant”; immunology

Funding. The study had no financial support.

Conflict of interest. The authors declare that there is no conflict of interest.

Contribution. Concept and design – Mirkhaidarov R.Sh., Valishin D.A.; data collection – Mirkhaidarov R.Sh.; statistical processing – Mirkhaidarov R.Sh., Kildebekova R.N.; writing, design – Mirkhaidarov R.Sh.; editing – Valishin D.A., Kildebekova R.N.

For citation: Mirkhaidarov R.Sh., Valishin D.A., Kildebekova R.N. Immunocorrection in treatment and prevention in liver fibrosis and chronic hepatitis С. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2023; 12 (1): 47–53. DOI: https://doi.org/10.33029/2305-3496-2023-12-1-47-53

References

1. Lioznov D.A., Dunaeva N.V., Chung N.H., Gorchakova O.V., Antonova T.V. Chronic hepatitis C: the current state of the problem. Nefrologiya [Nephrology]. 2019; 23 (4): 36–46. DOI: https://doi.org/10.24884/1561-6274-2019-23-4-36-46 (in Russian)

2. Konstantinov D.Yu., Konstantinova E.A., Sterbkova E.A., Popova L.L., Suzdal’tsev A.A. Individualization of antiviral treatment of chronic hepatitis. Eksperimental’naya i klinicheskaya gastoenterologiya [Experimental and Clinical Gastroenterology]. 2013; (6): 29–34. URL: https://cyberleninka.ru/article/n/individualizatsiya-protivovirusnogo-lecheniya-hronicheskogo-gepatita (in Russian)

3. Patlusov E.P., Ponezheva Zh.B., Mannanova I.V. The role of metabolic and immunological disorders in the progression of chronic hepatitis C. RMZh [Russian Medical Journal]. 2019; (10): 7–11. URL: http://www.rmj.ru/articles/infektsionnye_bolezni/Roly_metabolicheskih_i_immunologicheskih_narusheniy_v_progressirovanii_hronicheskogo_gepatita_S/#ixzz7lCNmw2l9 (in Russian)

4. Tamaki N., Kurosaki M., Higuchi M., et al. Genetic polymorphisms of IL28B and PNPLA3 are predictive for HCV related rapid fibrosis progression and identify patients who require urgent antiviral treatment with new regimens. PLoS One. 2015; 10 (9): e0137351. DOI: https://doi.org/10.3892/br.2021.1492

5. Baran B., Gulluoglu M., Soyer O.M., et al. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J Viral Hepat. 2014; 21 (2): 111–20. DOI: https://doi.org/10.1111/jvh.12127

6. Moon C., Jung K.S., Kim D.Y., Baatarkhuu O., Park J.Y., Kim B.K., et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci. 2015; 60 (2): 573–81. DOI: https://doi.org/10.1007/s10620-014-3361-6

7. Muldashev E.R. Theoretical and applied aspects of the creation of allografts «Alloplant» for facial plastic surgery. Saint Petersburg, 1995: 136 p. (in Russian)

8. Muslimov S.A. Morphological foundations of the use of allogeneic biomaterials in regenerative surgery. Ufa, 2001: 237 p. (in Russian)

9. Chernousov A.F., Khorobrykh T.V., Karpova R.V. Regeneration of liver tissue under the influence of cryoprecipitate and alloplant. Khururgiya [Surgery]. 2015; (7): 27–33. DOI: https://doi.org/10.17116/hirurgia2015727-33 (in Russian)

10. Galimov O.V., Timerbulatov M.V., Garifullin B.M. Method of treatment of toxic hepatitis and cirrhosis of the liver. Patent of the Russian Federation No. 2205647. Byul. No. 16 dated 10.06.2003. (in Russian)

11. Nartaylakov M.A., Mingazov R.S., Mustafin A.H., Musharapov D.R., Sokolov V.P., Galimov I.I. Application of allogeneic biomaterials in surgery of diffuse and cystic liver diseases. Meditsinskiy vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2007; 3–4: 25–35. (in Russian)

12. Aprelev A.E. Clinical and experimental substantiation and development of the pharmacopuncture method in the system of complex correction of myopia: abstract: Diss. Moscow, 2011: 23 p. (in Russian)

13. Kaybyshev V.T., Kil’debekova R.N., Sadykov F.A., et al. The effectiveness of dispersed biomaterial Alloplant in the complex therapy of duodenal ulcer. Meditsinskiy vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2016: 6 (66): 15–8. URL: http://cyberleninka.ru/article/n/effektivnost-dispergirovannogo-biomateriala-alloplant-v-kompleksnoy-terapii-yazvennoy-bolezni-dvenadtsatiperstnoy-kishki (in Russian)

14. Mirkhaydarova Z.M., Grushina T.I. Clinical efficacy of classical acupuncture and pharmacopuncture with biomaterial «Alloplant» in the conservative treatment of exudative otitis media. Fizioterapeft [Physiotherapist]. 2016; (4): 4–10. URL: http://elibrary.ru/item.asp?id=26630956 (in Russian)

15. Mirkhaydarov R.Sh., Kil’debekova R.N., Urazbakhtin R.K. Medico-economic efficiency of the use of dispersed biomaterial «Alloplant» in the treatment of dorsopathies. Problemy standartizatsii v zdravookhranenii [Problems of Standardization in Health Care]. 2013; (1–2): 33–5. (in Russian)

16. Mirkhaydarov R.S. Method of treatment of viral hepatitis or cirrhosis of the liver with biomaterial «Alloplant». Patent of the Russian Federation No. 2609252 dated 11.11.2015. (in Russian)

17. Guidelines for the care and treatment of chronic infection caused by hepatitis C virus. Geneva: World Health Organization, 2019. License: CC BY-NC-SA 3.0 IGO. (in Russian)

18. Vinnitskaya E.V., Drozdov V.N., Yunusova Yu.M., et al. Diagnostic significance of serum markers of fibrosis in chronic liver diseases. Terapevticheskiy arkhiv [Therapeutic Archive]. 2013; 85 (2): 27–31. URL: https://cyberleninka.ru/article/n/diagnosticheskaya-znachimost-syvorotochnyh-markerov-fibroza-pri-hronicheskih-zabolevaniyah-pecheni (in Russian)

19. Calvaruso V., Dhillon A.P., Tsochatzis E., et al. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. J Gastroenterol Hepatol. 2012; 27: 1227–32. DOI: https://doi.org/10.1111/j.1440-1746.2012.07136

20. Navrotsky A.N. Diagnostic capabilities of methods for assessing liver fibrosis in chronic viral hepatitis. Terapevticheskiy arkhiv [Therapeutic Archive]. 2016; 88 (11): 149–55. DOI: https://doi.org/10.17116/terarkh20168811149-155 (in Russian)

21. Gomez-Dominguez E., Mendoza J., et al. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther. 2008; 27: 441–7.

22. Baykova T.A., Lopatkina T.N. Diversity of extrahepatic manifestations of chronic viral hepatitis B and C, general principles of treatment. Therapeutic Archive. 2013; 85 (4): 106–10. URL: https://cyberleninka.ru/article/n/mnogoobrazie-vnepechenochnyh-proyavleniy-hronicheskih-virusnyh-gepatitov-v-i-s-obschie-printsipy-lecheniya (in Russian)

23. Gunyakova V.K. Mechanisms of apoptosis, its significance in the pathogenesis of viral hepatitis, possibilities of correction. Sibirskiy meditsinskiy zhurnal [Siberian Medical Journal]. 2005; (2): 5–13. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»